Clinical Trial Update: A Study of Response-Guided Duration of Combination Therapy With GS-9190, GS-9256, Pegasys® and Copegus® in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating a response-guided duration strategy for a four-drug regimen (GS-9190, GS-9256, pegylated interferon alfa-2a, and ribavirin) in previo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Copegus (ribavirin)
• GS-9190
• GS-9256
• Pegasys (pegylated interferon alfa-2a)

Snippet

Sponsor: Gilead Sciences | Conditions: Chronic Hepatitis C Infection | Phase 2 | Status: COMPLETED